Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2015 by Acceleron Pharma, Inc.
Sponsor:
Information provided by (Responsible Party):
Acceleron Pharma, Inc.
ClinicalTrials.gov Identifier:
NCT01727336
First received: November 8, 2012
Last updated: March 23, 2015
Last verified: March 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2018
  Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)